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Abstract
Background: Virus-like particle (VLP) platform represents a promising approach for the generation of efficient and
immunogenic subunit vaccines. Here, the feasibility of using grapevine fanleaf virus (GFLV) VLPs as a new carrier for
the presentation of human papillomavirus (HPV) L2 epitope was studied. To achieve this goal, a model of the HPV
L2 epitope secondary structure was predicted and its insertion within 5 external loops in the GFLV capsid protein
(CP) was evaluated.
Results: The epitope sequence was genetically inserted in the αB-αB” domain C of the GFLV CP, which was then
over-expressed in Pichia pastoris and Escherichia coli. The highest expression yield was obtained in E. coli. Using this
system, VLP formation requires a denaturation-refolding step, whereas VLPs with lower production yield were
directly formed using P. pastoris, as confirmed by electron microscopy and immunostaining electron microscopy.
Since the GFLV L2 VLPs were found to interact with the HPV L2 antibody under native conditions in capillary
electrophoresis and in ELISA, it can be assumed that the inserted epitope is located at the VLP surface with its
proper ternary structure.
Conclusions: The results demonstrate that GFLV VLPs constitute a potential scaffold for surface display of the
epitope of interest.
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Backgound
Virus-like particles (VLPs) are among the most easily-
produced nanomaterials, since they result from the self-
assembly of the capsid protein (CP). VLPs can be modified
either genetically or chemically for various downstream
applications i.e. as biomaterials [1], drug-delivery systems,
bio-imaging and chemical tools [2–4], for their catalytic
role [5–8] but also as vaccines [9–11]. Among the
different types of vaccines, the use of subunit vaccines has
been considered as a safer approach than that of inacti-
vated pathogens [12]. However, such small molecules, e.g.
composed of oligopeptides, act as weak immunogens [13].
A substantial increase in the immune response is observed
when relevant epitopes are placed on the surface of
macromolecular carriers, like large proteins or highly or-
dered structures such as VLPs [14].
Plant viruses are particularly interesting since they are
not infectious for humans and animals. Compared to
most animal viruses, the structure of the majority of
plant viruses is very simple and often made up of a sin-
gle CP type. Moreover, most of them are nonenveloped
and they present a very high level of accumulation in
their host [15–19]. In recent years, the potential use of
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plant virus-derived VLPs as novel proteic scaffold for dis-
playing foreign epitopes has been studied. Immunogenic
foreign peptides can be either genetically or chemically
fused to the plant virus CP. Some of these virus platforms
have been tested as potential subunit vaccines to prevent
human or animal viral diseases [15, 16, 20, 21].
VLPs based on several plant viruses were tested, in-
cluding cowpea mosaic virus (CPMV), alfalfa mosaic
virus, tobacco mosaic virus, potato virus C, tomato
bushy stunt virus, zucchini yellow mosaic virus, plum
pox virus, papaya mosaic virus, cucumber mosaic virus
and cowpea chlorotic mottle virus (CCMV) [22–27]. In
some cases, VLP assembly takes place under certain con-
ditions such as pH, ionic strength and presence of the
viral genomic RNA. Morever, the potential insertion
sites within the VLPs are usually limited based on the
protein structure [28]. Therefore, there is a need for
searching novel and versatile VLP systems. To this end,
grapevine fanleaf virus (GFLV) has not been extensively
studied as VLP-based platform for foreign epitope pres-
entation. GFLV is a bipartite, linear, single stranded
positive sense RNA genome virus which belongs to the
genus Nepovirus. Considering the structural features of
the GFLV capsid, it is composed of 60 copies of a single
coat protein (504 amino acids, 56 kDa) without any en-
velope. The ternary structure of the CP subunit is de-
fined by three jelly-roll domains named C, B and A from
the N- to C- termini, respectively. The viral structure
has been elucidated at 2.7 Å resolution [29].
Recently, GFLV VLPs have been transiently expressed
using pEAQ-HT vector in Nicotiana benthamiana [30].
These authors showed that epitopes inserted in the N-
and C-termini were exposed on the particle surface.
However, no study related to insertion sites within the
internal domains of GFLV VLP is available. To the best
of our knowledge, the in vitro assembly of GFLV VLPs
has never been studied.
VLPs from plant viruses have been produced in vari-
ous microbial expression systems, namely Escherichia
coli, Pseudomonas fluorescens, Pichia pastoris and Sac-
charomyces cerevisiae [26, 31–34]. These expression sys-
tems include prokaryotic and eukaryotic organisms, each
having its own advantages and drawbacks. Indeed, pro-
duction in prokaryotic systems is generally cost-effective
and can take place in a short period of time. However,
the lack of post-translational modifications and the pres-
ence of endotoxins are the most intriguing problems
when using these systems [35]. Moreover, since large
amount of proteins is often produced in an insoluble
form, extra denaturation and refolding processes may be
required, as it was the case for CCMV [26]. Concerning
the yeast expression system, the quantity of the pro-
duced proteins is usually lower than in E. coli. Neverthe-
less, soluble proteins are obtained without an extra
solubilization step. Moreover, this system is easy to ma-
nipulate and offers high expression yields as well as ease
of scale-up [36].
High-risk genotypes of human papillomavirus (HPV)
are responsible for cancers in females and males.
Around 70 % of the cervical cancers are due to HPV16
and 18 genotypes [37]. The current vaccines are based
on the major capsid protein (L1) giving rise to a HPV
type-restricted protection. Instead, the HPV minor cap-
sid protein (L2) contains cross-type neutralizing epitopes
that broaden protection against various HPV types when
they are displayed on a VLP platform [21]. HPV L2 epi-
topes (up to 36 amino acids) have been displayed on
VLPs of HPV16 L1, bacteriophages PP7, MS2 and potato
virus X that were expressed in baculoviruses, bacteria
and plants [21, 38–40].
Here we have studied the feasibility of using GFLV
VLPs as scaffold for HPV L2 epitope presentation albeit
maintaining VLP formation. To achieve this goal, GFLV
VLPs displaying HPV L2 epitope as well as GFLV CP
VLPs were expressed in both Escherichia coli and Pichia
pastoris systems.
Results
GFLV-L2 VLP modeling and selection of the epitope
insertion and fusion site
For GFLV-L2 VLP modeling, the secondary structures of
the GFLV CP and the selected HPV L2 epitope (amino
acids 17–31) were needed. The GFLV CP 3D structure
was previously solved by [29] (Protein Data Bank (PDB)
ID: 4V5T). In the absence of a resolved structure for the
HPV L2 epitope as well as of potential structural tem-
plates in PDB using the selected sequence, the secondary
structure model of the HPV L2 epitope was constructed
by examining small epitope fragment secondary struc-
tures in Protein Design Assistant (ProDA) and by using
information about HPV L2 structure obtained from a
previous study performed by Tumban and coworkers
[21]. These authors showed that the targeted HPV L2
region contains two cysteine residues (C22 and C28)
which form a disulfide bond in their native conformation
and both cysteine residues are conserved throughout the
Papillomaviridae. We have assumed that the disulfide
bond between the HPV L2 cysteine residues creates a
turn structure (Fig. 1a). The HPV L2 epitope sequence
was divided into three parts, namely QLYKT, CKQAGTC
and CPPD, which were used as query sequences in
ProDA. The structural template of the QLYKT sequence
was that from amino acids 416–420 of methionyl-tRNA
synthetase protein (PDB-ID: 3H9C) (Fig. 1b) that forms
an α helix structure. For the CKQAGTC part, the closest
structural template having a turn structure with a disulfide
bond was amino acids 103–109 of disulfide bond oxidore-
ductase D (DsbD) protein (PDB-ID: 1L6P) (Fig. 1c). For
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the third part, amino acids 402–405 of botrocetin protein
was used as structural template (PDB-ID: 1FVU) (Fig. 1d).
Finally, the PDB files of the described structures were used
as templates to model HPV L2 epitope using MODELLER
software [41] (Fig. 1e).
Based on the GFLV CP 3D structure obtained from
YASARA software, 5 insertion sites for the foreign
epitope were investigated, namely amino acid residues
14–17 (βB-βC domain C), 79–85 (αB-αB” domain C),
190–195 (βB-βC domain B), 211–212 (βC-βC” domain
B), 375–378 (βC-βC” domain A). These sites were as-
sumed to have at least one advantage for the insertion of
foreign epitopes, i.e. the fact that the inserted epitope
would be displayed on the surface of the particle since
these regions are located in the outer area of the particle
(Fig. 2a); The 190–195, 211–212 and 375–378 loops
were found to be unsuitable as insertion regions. Indeed,
they are located between two sheets and deletion/in-
sertion or replacement in these loops would probably
disturb β-barrel structures and have a critical effect
on the conformational structure. Two insertion sites,
amino acids 79–85 and 14–17, would have most
likely a minimal impact on the particle formation,
meaning that an insertion in these loops would not
interfere in protein-protein interactions. Finally, the
79–85 loop was selected for the insertion of the HPV
L2 epitope on the GFLV VLP surface. The distance
between both ends of the 79–85 loop (about 10 Å)
was similar to that between both ends of the HPV L2
epitope. It was assumed that the HPV L2 epitope
would have a better conformational flexibility in the
79–85 loop than in the 14–17 loop and that a disul-
fide bond will be formed in this loop (Fig. 2b) (de-
tailed information is not shown).
Fig. 1 Secondary structure model of HPV L2 epitope (amino acids 17–31). a HPV L2 epitope sequence with the identified disulfide bond, (b)
Structural template for the QLYKT sequence (PDB-ID: 3H9C), (c) Structural template for the CKQAGTC sequence (PDB-ID: 1L6P), (d) Structural
template for the CPPD sequence (PDB-ID: 1FVU), (e) HPV L2 epitope secondary structure model
Fig. 2 HPV L2 epitope display site on GFLV VLPs. GFLV structure was established according to data from PDB ID: 4V5T, and visualized by YASARA
software (http://www.yasara.org/). a Ribbon diagram of the GFLV CP displaying 5 loops, 14–17 (βB-βC domain C), 79–85 (αB-αB” domain C), 190–
195 (βB-βC domain B), 211–212 (βC-βC” domain B), 375–378 (βC-βC” domain A) as potential insertion sites, (b) GFLV particle showing an
icosahedral asymmetric unit consisting of one identical subunit. The arrow indicates the 79–85 (αB-αB” domain C) external loop on GFLV CP
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Cloning, expression and production of GFLV VLPs in E.
coli
Restriction enzyme analysis confirmed that the GFLV CP
and GFLV L2 genes (1.5 kb) were inserted in the pET26B
vector between NcoI-BamHI cloning sites. Further, nucleo-
tide sequencing using specific primers confirmed the inser-
tion of the GFLV CP and GFLV L2 genes in frame with
pelB leader sequence without anymutation. Additional file 1:
Figure S1A shows a SDS-PAGE analysis of protein expres-
sion in E. coli strains BL21 (DE3). The detection of a dis-
tinct band at 56–57 kDa in lanes 3 and 4 indicates that
large amounts of the recombinant GFLV CP and GFLV L2
in an insoluble form were produced in E. coli.
Various expression conditions were examined in order
to obtain the GFLV CP and GFLV L2 in a soluble form in
E. coli, such as different E. coli strains (BL21 and SHuffle
T7 cells), induction times (2, 4, 6 and 8 h), isopropyl β-D-
1-thiogalactopyranoside (IPTG) concentrations (0.25, 0.5
and 0.8 mM) and growth temperatures (15, 25 and 37 °C).
However, under all tested conditions, the proteins were
expressed as inclusion bodies (IBs). The highest expres-
sion yield was obtained using the strain BL21 (DE3), 0.25
mM IPTG at 37 °C during 4 h in a shaker.
To solubilize the proteins of interest, different solutions
containing one or several compounds were tested (8M
urea and 1% triton X-100; 8M urea, 1% triton X-100 and
10mM dithiothreitol (DTT); 8M urea, 1% triton X-100,
10mM DTT and 14mM mercaptoethanol, pH = 8 for 4
and 6 h at 4 °C; 10mM SDS and 15mM DTT; 8M urea
and 10mM DTT, pH = 7 for 16 h at 4 °C). The IBs were
found to be solubilized in solutions containing 10mM
SDS and 15mM DTT or 8M urea and 10mM DTT, pH=
7 for 16 h at 4 °C. The solubilization of the IBs in the solu-
tion containing urea during 16 h at 4 °C was found to be
the best protocol. Indeed, as shown in Additional file 1:
Figure S1B, the GFLV CP and GFLV L2 were almost com-
pletely solubilized under these conditions. The proteins
were then purified by size exclusion chromatography
(SEC) using a Superdex 200 column. For the VLP assem-
bly from the purified GFLV CP and GFLV L2, different
buffers were evaluated. It was found that an acidic pH and
a high ionic strength led to protein aggregation at both
temperatures (4 and 25 °C). The GFLV CP and GFLV L2
were found to self-assemble into VLPs after two steps of
dialysis in HEPES buffer at pH 8 and 4 °C. GFLV VLPs
were then concentrated by sucrose cushion ultracentrifu-
gation. As can be seen in Additional file 1: Figure S1C,
highly purified GFLV CP and GFLV L2 VLPs could be
obtained (estimated purity: 94 and 93%, respectively).
Cloning, expression and production of GFLV VLPs in P.
pastoris
The correct sequences and frames for sequential transla-
tion of the α-factor and GFLV CP or GFLV L2 fragments
into pPICZα were confirmed by sequencing. GFLV CP
and GFLV L2 were expressed after three days of culture
and in the presence of 2% methanol. They were secreted
into the culture medium along with the α-factor signal
which was cleaved by the Kex2 protease. The supernatants
from the positive colonies that grew in the highest con-
centration of Zeocin™ were analyzed by SDS-PAGE after
concentration by ultracentrifugation (cf. Additional file 2:
Figure S2A). As shown in this Figure, A1 clone of GFLV
CP and A3 clone of GFLV L2 (lanes 1 and 3) were found
to secrete high protein levels while the GFLV CP and
GFLV L2 were not expressed in A2 and A4 clones, re-
spectively (lanes 2 and 4). The proteins of interest were
not observed in the culture of P. pastoris transformed with
the empty pPICZα vector in the presence of methanol
(lane 5). The cultures of the selected clones were concen-
trated by sucrose cushion ultracentrifugation (cf. Add-
itional file 2: Figure S2B; estimated purity: 97% for GFLV
CP VLPs and 98% for GFLV L2 VLPs).
Characterization of the capsid proteins
Western blot analysis using an antibody directed against
the GFLV CP showed the presence of the protein of
interest for the GFLV L2 samples (cf. Fig. 3a (E. coli)
and c (P. pastoris), lane 2), indicating that the GFLV
antibody interacts with the GFLV L2 protein, as is the
case for the GFLV CP (cf. Fig. 3a and c, lane 1).
Immunoblotting directed against the HPV L2 epitope
confirmed its presence in the GFLV-L2 protein (cf. Fig.
3b (E. coli) and d (P. pastoris), lane 1). Considering the
absence of a band at the corresponding MW for the
GFLV sample (cf. Fig. 3b (E. coli) and d (P. pastoris),
lane 2), it can be assumed that the GFLV CP does not
interact with the HPV L2 antibody, which therefore con-
firms that this antibody specifically detects the HPV L2
epitope in the GFLV L2 protein.
Characterization of the GFLV VLPs
GFLV VLP pellets from both expression systems were
resuspended in the virus buffer (0.1 M HEPES, 0.001M
EDTA, pH 8). VLPs were analyzed by SEC and a major
peak was observed at 1.3 mL in both cases (Add-
itional file 3: Figure S3). The final yield of VLPs from E.
coli was 15–20mg/L while that from P. pastoris was 1–
3 mg/L. Transmission electron microscopy (TEM) ana-
lysis showed a population of spheroid particles having a
diameter of 29 ± 1.5 nm and 31.9 ± 2.5 nm in E. coli
(Fig. 4A, a and b) and P. pastoris (Fig. 4B, a and b),
respectively. This indicates that the GFLV CP and GFLV
L2 are capable of self-assembly into VLPs in vitro (E.
coli) and in vivo (P. pastoris). In agreement with the
TEM results, the immunostaining electron microscopy
(ISEM) analysis confirmed the presence of GFLV VLPs
obtained from E. coli and P. pastoris that clearly
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immunoreact with anti-GFLV CP polyclonal antibody
(Fig. 5a-d). It should be noted that when polyclonal sera
from mice immunized with HPV16 L2 peptide 1–88
were used as primary antibody, the staining was too
weak to draw a conclusion about the interaction be-
tween GFLV L2 VLPs and HPV L2 antibody.
Both GFLV VLPs were evaluated in ELISA using anti-
GFLV CP and an antibody directed against amino acids
1–40 of HPV16 L2 (cf. Fig. 6). ELISA analysis using
anti-GFLV CP confirmed the formation of GFLV VLPs
in P. pastoris and E. coli systems. Moreover, the inser-
tion of HPV L2 epitope did not interfere with VLP
formation. ELISA analysis using anti-HPV L2 antibody
demonstrated the interaction of the antibody with GFLV
L2 VLPs, indicating that the HPV L2 epitope is located
on the VLP surface.
Capillary electrophoresis (CE) is a very powerful tech-
nique that allows the analysis of intact viral particles but
also the study of biomolecular interactions under native
conditions [42]. It is worth noting that the interaction of
a viral particle with an antibody may lead to the appear-
ance of a peak corresponding to the virus-antibody com-
plex. However, if the binding of the antibody with the
virus results in the aggregation of several particles, the
virus-antibody complex may not be detected [43]. GFLV
CP and GFLV L2 VLPs were first incubated during 1 h
Fig. 3 Western blot analysis of the GFLV CP and GFLV L2 VLPs expressed in E. coli (a and b) and in P. pastoris (c and d). a and c: blots were
probed with anti-GFLV CP polyclonal antibody. Lane M: standard protein molecular weight markers, lane 1: GFLV CP, lane 2: GFLV L2, lane 3:
negative control (E. coli with pET26 empty vector or P. pastoris with pPICZα empty vector). b and d: blots were probed with mouse anti-HPV L2
antibody. Lane M: standard protein molecular weight markers, lane 1: GFLV L2, lane 2: GFLV CP
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at room temperature with the GFLV antibody and the
mixtures were then analyzed by CE (cf. Fig. 7A and B). As
shown in these figures, both VLP samples were found to
interact with the GFLV antibody as the VLP peak disap-
peared in the presence of the antibody. The CE experi-
ments were then performed using the antibody directed
against amino acids 1–40 of HPV16 L2 (cf. Fig. 7C and
D). GFLV CP and GFLV L2 VLPs were also incubated
during 1 h with the antibody before the CE analysis. As
expected, GFLV CP VLPs did not interact with the HPV
L2 antibody (cf. Fig. 7C). Indeed, following the incubation
with this antibody, the VLP peak was still present and the
ratios of the corrected area to that of the internal standard
were the same under both conditions. Regarding the
GFLV L2 sample, a complex was formed when the VLPs
were incubated with the HPV L2 antibody since a peak
with a longer migration time appeared (cf. Fig. 7D).
GFLV VLPs are nucleic acid-free
The agarose gel electrophoresis of the RT-PCR products
of GFLV CP and GFLV L2 mRNA that was amplified
using one set of specific primers showed that CP mRNA
was not encapsidated into VLPs produced from E. coli
(lanes 1–2, Additional file 4: Figure S4) and from P. pas-
toris (lanes 3–4, Additional file 4: Figure S4). According
to these results, it can be concluded that GFLV VLPs as-
semble independently from RNA.
Discussion
The discovery of a rational VLP system for displaying
epitopes of interest is obviously a challenging effort. In-
deed, the scaffolding protein has to present a potential
flexibility for any changes and the functionality of the
epitope has to be preserved. Here we present a VLP
Fig. 4 Ultrastructural analysis of VLPs obtained from E. coli (A) and from P. pastoris (B), a GFLV CP VLPs, b GFLV L2 VLPs, c negative control (E. coli
with pET26 empty vector or P. pastoris with pPICZα empty vector). Scale bar: 50 nm. Arrows indicate viral particles visualized at high
magnification in the inserts (scale bar in the inserts: 30 nm)
Fig. 5 Immuno-gold labeling analysis of chimeric VLP expressed in E. coli and P. pastoris. Anti-GFLV CP polyclonal antibody is used as primary
antibody. a GFLV CP VLPs from E. coli, (b) GFLV L2 VLPs from E. coli, (c) GFLV CP VLPs from P. pastoris, (d) GFLV L2 VLPs from P. pastoris. Scale
bar: 100 nm
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Fig. 6 Characterization of GFLV CP and GFLV L2 VLPs by ELISA. Serial dilutions of (a) anti-GFLV CP and (b) anti-HPV L2 were tested in triplicates
against GFLV CP and GFLV L2 VLP antigens. Leaf tissue infected by GFLV was used as positive control. The negative control was E. coli with pET26
empty vector
Fig. 7 CE analysis of complex formation between GFLV CP VLPs (A) or GFLV L2 VLPs (B) and GFLV antibody. a VLPs analysis without antibody, b
VLPs incubated with 200 fold molar excess of GFLV antibody during one hour at room temperature before injection. CE analysis of complex
formation between GFLV CP VLPs (C) or GFLV L2 VLPs (D) and HPV L2 antibody. a VLPs analysis without antibody, b VLPs incubated with 39 fold
molar excess of HPV L2 antibody during one hour at room temperature before injection. Peak 1, IS; peak 2, VLP; peak 3, GFLV L2 VLPs / HPV L2
antibody complex; BGE, 0.01 M Tris HCl, 0.01 M HEPES-Na, 0.1 M NaCl and 0.1% PEG 6000, pH 7.4 buffer containing 0.2% Tween 20 and 1.5 mM
SDS; 48.5 cm (8.5 cm to the detector) × 50 μm PEO-coated capillary; voltage + 10 kV; pressure injection for 15 s at − 50mbar; T = 15 °C; Detection
at 280 nm
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platform based on GFLV particles to expose HPV L2
epitope on its surface without interfering in VLP
formation.
Based on in silico data, loop structures βB-βC and αB-
αB” (domain C) were predicted as epitope insertion sites
and the latter was selected for expression experiments.
Expression of GFLV constructs in E. coli ended up in
the formation of IBs. This was already reported for other
plant VLP systems like CCMV and Faba bean necrotic
yellows virus [26, 44]. This might be due to the presence
of intra- and inter-molecular disufide bonds in cysteine-
rich proteins, as is the case for GFLV CP [45]. To
solubilize GFLV expressed in E. coli, an extra step was
developed. This step is required for VLP formation, as
also shown for CCMV VLPs [26]. TEM examination of
GFLV L2 VLPs showed the presence of spherical parti-
cles similar to GFLV particles indicating that the inser-
tion of the HPV L2 sequence does not abolish VLP
formation. In addition, the expression of the GFLV CP
and GFLV L2 within P. pastoris, ended up with the for-
mation of VLPs, as already reported for CCMV [33].
When comparing both expression systems used in this
study, it can be concluded that in E. coli, the use of a fast
and easy process results in a higher amount of the pro-
tein than in P. pastoris. However, in yeast, soluble pro-
teins are obtained without an extra solubilization step.
GFLV particles can also be produced in N. benthamiana
but it is worth noting that the amount of protein is very
low (386 to 445 μg/kg fresh leaf) [30]. Transient expres-
sion has also been used for the production of other plant
virus-derived VLPs, such as CPMV [46], turnip crinkle
virus [47] and Ageratum yellow vein virus [48]. Unlike
bacterial expression systems, plants are able to provide
post-translational maturations such as glycosylation and
also reduce the risk of endotoxin contamination [49].
From the GFLV CP 3D structure, it could be deduced
that the selected 79–85 loop of all sixty CP subunits is
surface accessible. The insertion in this loop did not
interfere in the CP- CP interactions necessary for VLP
assembly and stability and resulted in the exposure of
the HPV L2 epitope at the particle outer surface in its
native conformation. In agreement with our results,
Schellenberger et al. reported that the replacement in
the CP region R1 of GFLV (amino acids 79–85) to CP
region R1 of Arabis mosaic virus, which is located at the
external surface of the particles, did not interfere with
virus encapsidation [50].
Since GFLV L2 VLPs were found to interact with the
HPV L2 antibody under native conditions in capillary
electrophoresis and in ELISA, it can be assumed that the
inserted epitope is located at the VLP surface with its
proper ternary structure. This is obviously crucial for
the use of GFLV L2 VLPs as a potential vaccine. Previ-
ous studies reported that this HPV L2 epitope located at
the N-terminal part of MS2 phage has more conform-
ational flexibility than in the AB-loop of PP7 phage,
allowing the formation of a disulfide bond in the epitope
and leading to a better presentation of the peptide, indu-
cing a more broadly reactive antibody response against
the HPV L2 epitope [21, 51].
The absence of GFLV mRNA was confirmed using
purified VLPs as input for RT-PCR. However, the encap-
sulation of non-specific mRNA and DNA within the
VLPs cannot be excluded. To avoid any encapsulation of
nucleic acids, the subunits might be treated using RNa-
seA and DNase before VLP formation.
Conclusions
In this study, the generation of a new icosahedral VLP
carrier through the cloning and expression of the GFLV
CP and GFLV L2 genes in E. coli and P. pastoris was
demonstrated. VLPs containing an epitope from the
HPV minor CP (HPV L2 epitope) were obtained. The
application of GFLV L2 VLPs as a promising vaccine
antigen will be clear after immunization tests. Besides
loop αB-αB”, βB-βC loop might be investigated as an-
other insertion site for possible divalent exposure of can-
didate peptides at the same time.
Methods
Prediction of HPV L2 epitope structure and insertion sites
in GFLV VLP
Since the crystal structure of HPV L2 minor protein is not
available, the secondary structure model of the HPV L2
epitope (NH3-QLYKTCKQAGTCPPD-COOH) was con-
structed by examining small epitope fragments in Protein
Design Assistant (ProDA; http://bioinf.modares.ac.ir/soft
ware/linda/). To this end, the HPV L2 epitope sequence
was divided into three parts, namely QLYKT, CKQAGTC
and CPPD, which were used as query sequences in
ProDA. Finally, the PDB files of the described structures
were used as templates to model HPV L2 epitope using
MODELLER software [41]. The model was visualized with
YASARA software (http://www.yasara.org/).
The GFLV CP PDB code [29] was used as input to
search for potential insertion sites using YASARA
software.
Construction and expression of GFLV CP and GFLV L2 in
E. coli
To produce pBluescript II SK-GFLV-L2 construct, GFLV
L2 gene was synthesized and cloned into the NcoI and
BamHI sites by BioBasic Company (Toronto, Canada).
pGEM-GFLV CP [52] and pBluescript II SK-GFLV-L2
were used as templates for amplification of GFLV CP and
GFLV L2 genes using a primer set (Sense primer:5′-CCA
GCC GGC GAT GGC CAT GGG ATT AGC TGG TAG
AGG-3′; antisense primer: 5′-ACG GAG CTC GAA TTC
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GGA TCC CTA GAC TGG GAA ACT GGT TCT CCA-
3′ which includes two homologous region CCA GCC
GGC GAT GGC and ACG GAG CTC GAA TTC GGA
TCC) and Phusion High Fidelity DNA polymerase (New
England Biolabs, Ipswich, MA, USA). The amplified frag-
ments were subcloned in the pET26 vector in frame with
the pelB leader sequence using the Gibson assembling
cloning master mix for 15min at 50 °C (New England
Biolabs) and transformed into E. coli DG1 (Eurogentec,
Liege, Belgium). The grown colonies were tested and ana-
lysed using colony PCR, digestion analyses and sequencing
to confirm GFLV CP and GFLV L2 constructs. Finally, the
positive plasmids were transformed into E. coli BL21
(DE3) (New England Biolabs) using the calcium chloride
transformation method.
E. coli strains BL21 (DE3) transformed with pET26
GFLV CP and pET26 GFLV L2 were grown overnight in
Luria–Bertani (LB) medium containing 50mg/L kanamy-
cin. One mL of the overnight culture was added to 100
mL of fresh LB culture medium and incubated at 37 °C.
When the OD600 reached a value of 0.8–1, 0.1–0.25mM
IPTG was added and the cultures were incubated at 18–
37 °C for 1–4 h. Pelleted cells were collected by centrifuga-
tion and stored at − 20 °C for use in subsequent steps. The
negative control was empty pET26 vector.
In vitro denaturing and refolding of GFLV VLPs produced
by E. coli
To solubilize GFLV CP and GFLV L2 proteins, a process
of denaturing and refolding was adapted from a previous
work [26] with some modifications. The insoluble pro-
teins produced in E. coli were dissolved in 15mL of dis-
assembly buffer (0.02M Tris-HCl, 0.01M DTT and 8M
urea, pH 7) with slow rotation during 16 h at 4 °C. The
dissolved proteins were centrifuged at 16000 rpm for 15
min. The supernatants were filtered and purified by SEC
using a Superdex 200 column. SEC runs were performed
at a constant flow rate of 2 mL/min using the disassem-
bly buffer (0.02M Tris-HCl, 0.01M DTT, 8M urea, pH
7) containing 2.5 M NaCl as eluent. Twenty μL of the
peak fractions were analysed by SDS-PAGE. The frac-
tions containing the purified GFLV CP and GFLV L2
were dialyzed 6 times against the dialysis buffer (0.02M
Tris-HCl, pH 7) and were refolded using 2 cycles of
dialysis against the reassembly buffer (0.1 M HEPES, pH
8). Finally, the GFLV VLPs concentrated using ultracen-
trifugation were dissolved in the virus buffer (0.1 M
HEPES, 0.001M EDTA, pH 8) (Merck, Darmstadt,
Germany).
Construction of recombinant P. pastoris
The PCR of the GFLV CP and GFLV L2 genes were
done using a primer set (sense primer: 5′- AAG AAG
GGG TAT CTC TCG AGA AAA GAG AGG CTG
AAG CTA TGG GAT TAG CTG GTA GAG GAG − 3′;
antisense primer:5′- GCT GGC GGC CGC CGC CTA
GAC TGG GAA ACT GGT TCT − 3′ which includes
two homologous regions AAG AAG GGG TAT CTC
TCG AGA AAA GAG AGG CTG AAG CTA and GCT
GGC GGC CGC CGC, respectively) and the recombin-
ant plasmid (pPICZα-CP) with α-factor sequence was
constructed by Gibson assembly method [53]. Five-ten
μg of pPICZα-CP DNA plasmid were linearized using
PmeI enzyme and introduced in P. pastoris X-33 by elec-
troporation as described in the Pichia Expression Kit
protocol (Invitrogen, Carlsbad, CA, USA).
Selection of multiple copy recombinant genes in P.
pastoris
The PCR-positive colonies on YPDS-Zeocin™ (100 mg/
mL) agar plates were cultured in 250 μL YPD medium
and incubated for 48 h at 28–30 °C. Ten μL of each
culture was then recultured in 240 μL fresh YPD
medium and incubated at 30 °C for 24 h. This step was
repeated 3 times. Ten μL of the last microplate was cul-
tured in 240 μL fresh YPD medium with three concen-
trations of Zeocin™, i. e. 0.25 mg/mL, 0.5 mg/mL and 1.0
mg/mL. The microplates were incubated for 3–4 days at
30 °C until the cells grew.
Laboratory scale yeast cell density and total protein
expression
Sixty μL of the selected transformants were inoculated
into 5 mL YPD medium and shaked at 200 rpm for 16–
18 h at 30 °C. Afterwards, 20 mL of BMGY medium were
inoculated with 250 μL of YPD culture and incubated as
described above. When the OD600 had a value of 2–6, a
centrifugation at 4800 rpm for 10 min was performed.
Pelleted cells were resuspended in 20 mL of BMMY
medium and incubated at 28 °C until the OD600 reached
a value of 2–6. Sterile pure methanol (final concentra-
tion of 2%) was then added every 24 h to maintain in-
duction. Every 12 h, 1 mL of the induced culture was
sampled and 1mL of BMMY medium was added to keep
the original volume of the culture, for the determination
of the protein expression level in the supernatant by
SDS-PAGE and Western blotting. All materials used in
the culture media were purchased from Sigma Aldrich
(Saint-Louis, MO, USA).
Purification and concentration of GFLV VLPs
The cultures of P. pastoris containing the expressed pro-
tein were first centrifuged (10,000 g) for 30min. The su-
pernatants were centrifuged at 73,360 g (Beckman Type
30 rotor, Brea, CA, USA) for 2 h to pellet VLPs [33]. VLPs
were resuspended in the virus buffer and further purified
by the sucrose cushion centrifugation. For this purpose, 2
mL of the VLP suspensions were added to 15mL of 20%
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sucrose solution (w/v) and centrifuged at 40,000 rpm for
3 h. VLP pellets were again resuspended in the virus buffer
and dialyzed against the virus buffer. For the concentra-
tion of the GFLV VLPs produced in E. coli, the sucrose
cushion method described above was also applied.
SDS-PAGE and Western blotting
The proteins expressed in both systems were analyzed in a
12% SDS-PAGE gel followed by Western blot (Bio-Rad,
Hercules, CA, USA). Western blotting analysis was per-
formed using anti-GFLV CP polyclonal antibody (1:1000)
(DSMZ, Braunschweig, Germany) and mouse anti-L2
polyclonal sera (kindly provided by Dr. Ebenezer Tumban,
Department of Molecular Genetics and Microbiology,
University of New Mexico School of Medicine). The de-
velopment of the signals was carried out using the Super
Signal West Pico Chemiluminescent Substrate (Thermo
Scientific, Waltham, MA, USA) (Amersham™ Imager 600).
Transmission electron microscopy (TEM) and
immunostaining electron microscopy (ISEM)
GFLV VLPs were analyzed by TEM (Jeol JEM-1400, Jeol,
Zaventem, Belgium). For this purpose, 10 μL of the sam-
ples, previously diluted 10–15 times in the virus buffer
were placed on 400 mesh copper grids (Laborimpex,
Brussels, Belgium) for 2min followed by negative staining.
The mean particle diameter was determined on the basis
of the analysis of 20 particles. The ISEM was performed
following the procedure published by [54]. Thirty μL of
the samples were placed on 200 mesh Formvar/Carbon
Nickel grids (Laborimpex) for 60min, followed by block-
ing using PBS buffer containing 1% bovine serum albumin
(BSA) for 20min. Anti-GFLV CP polyclonal antibody (1:
100) or anti-L2 polyclonal sera (kindly provided by Dr.
Ebenezer Tumban) was used as primary antibody and goat
anti-rabbit-gold (10 nm) conjugates (AURION, Wagenin-
gen, Netherlands) were employed as secondary antibody
at a 1:40 dilution in PBS buffer for 60min (supplemented
with 0.2% BSA and normal goat serum, 1:50). After 5
washing steps, samples were postfixed for 10min in 2.5%
glutaraldehyde and counterstained using 2.5% uranyl acet-
ate for 10min followed by 4 washes and an incubation of
10min in lead citrate. Grids were finally washed 4 times
in deionized water and examined by TEM (Jeol JEM-
1400) at 80 kV using GFLV virion derived VLPs as a posi-
tive control. When the secondary antibody was omitted,
no label occurred (data not shown).
ELISA
To confirm VLP formation and to evaluate the exposition
of HPV L2 epitope on the VLP surface, ELISA analysis
was performed as previously described in [55, 56]. VLP
antigens were diluted in 0.1M PBS (pH 7.2; final concen-
tration: 1000 ng/mL) and kept on ice prior to the analysis.
VLPs were tested using serial dilutions of rabbit anti-
GFLV polyclonal antibody (1:500, 1:1000, 1:2000, 1:3000)
(DSMZ) and mouse monoclonal antibody raised against
amino acids 1–40 of HPV16 L2 (1:500, 1:1000, 1:2000, 1:
3000) (Santa Cruz, Heidelberg, Germany). Goat anti-
rabbit-IgG and goat anti-mouse-IgG alkaline phosphatase
conjugates (1:3000) (Promega, USA) were used as second-
ary antibodies. The wells were developed in 4-nitrophenyl
phosphate disodium salt hexahydrate (Sigma-Aldrich) and
the absorbance was measured using an ELISA reader
Anthos 2020 at 405 nm.
Size exclusion chromatography (SEC)
VLPs were purified by size exclusion chromatography on
a 2 mL column of Sephacryl 300 using 100 mM HEPES
and 0.001M EDTA (pH 8) buffer.
Capillary electrophoresis (CE)
The experiments were performed on a HP3D CE system
(Agilent Technologies Waldbronn, Germany). This instru-
ment is equipped with an autosampler and a temperature
control system (15–60 °C ± 0.1 °C). The detection was car-
ried out using an on-column diode array detector. UV de-
tection was set at 280 nm. Bare fused-silica capillaries with
an internal diameter of 50 μm were purchased from
Optronis (Kehl, Germany). Capillaries of 48.5 cm total
length (8.5 cm effective length) were dynamically coated
with poly (ethylene oxide) (PEO) according to the proced-
ure previously reported by [57]. Experiments were per-
formed using the outlet injection mode. VLP samples
were injected hydrodynamically by applying a pressure of
− 50mbar during 15 s. Anti-GFLV antibody (DSMZ) and
mouse monoclonal antibody raised against amino acids
1–40 of HPV16 L2 (Santa Cruz) were used for affinity ex-
periments. The separation was performed applying a volt-
age of 10 kV (normal polarity mode) and the capillary was
thermostated at a temperature of 15 °C.
Detection of nucleic acid in GFLV VLPs
RT-PCR test was performed to evaluate the presence or
the absence of nucleic acid in GFLV VLPs. Total RNA
was purified from VLPs using Trizol according to the
manufacturer’s instructions (Invitrogen, Carlsbad, CA,
USA) and specific primers of GFLV CP were used for
the detection of viral mRNA in the VLPs.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
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Additional file 1: Figure S1. (A) SDS–PAGE analysis of the protein
expression in E. coli. Lane M: unstained PageRuler® molecular weight
markers, lane 1: Total fraction of GFLV-L2, lane 2: soluble fraction of GFLV-
L2, lane 3: insoluble fraction of GFLV-L2, lane 4: insoluble fraction of GFLV
CP. (B) SDS–PAGE analysis after application of the solubilisation protocol.
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Lane M: unstained PageRuler® molecular weight markers, lane 1: pellet
fraction of GFLV CP, lane 2: pellet fraction of GFLV L2, lane 3: supernatant
fraction of GFLV CP, lane 4: supernatant fraction of GFLV L2. (C) SDS–
PAGE analysis after sucrose cushion ultracentrifugation. Lane M: unstained
PageRuler® molecular weight markers, lane 1: GFLV CP VLPs, lane 2: GFLV
L2 VLPs. The proteins of interest are indicated by an arrow. Gels were
stained with coomassie blue.
Additional file 2: Figure S2. (A) SDS-PAGE analysis of the GFLV VLP
samples expressed in P. pastoris. Lane M: unstained PageRuler® molecular
weight markers, lane 1: clone A1 of GFLV CP, lane 2: clone A2 of GFLV
CP, lane 3: clone A3 of GFLV L2, lane 4: clone A4 of GFLV L2, lane 5: nega-
tive control (P. pastoris with pPICZα empty vector). (B) SDS–PAGE analysis
of the GFLV VLP samples expressed in P. pastoris after sucrose cushion
ultracentrifugation. Lane M: unstained PageRuler® molecular weight
markers, lane 1: clone A1 of GFLV CP, lane 2: clone A3 of GFLV L2. Gel
was stained with coomassie blue.
Additional file 3: Figure S3. Size exclusion chromatography (SEC)
analysis of GFLV VLPs using a Sephacryl 300 column (absorbance at 280
nm). (A) SEC analysis of the VLPs produced in E. coli, a GFLV CP VLPs, b
GFLV L2 VLPs. (B) SEC analysis of the VLPs produced in P. pastoris, a GFLV
CP VLPs, b GFLV L2 VLPs.
Additional file 4: Figure S4. Analysis of RT-PCR products of GFLV CP
and GFLV L2 mRNA by agarose gel electrophoresis. Lanes 1–2: nucleic
acids extracted from 200 μL GFLV CP and GFLV L2 VLPs samples from E.
coli, lanes 3–4: nucleic acids extracted from 200 μL GFLV CP and GFLV L2
VLPs samples from P. pastoris. Lane 5: positive control (i.e. nucleic acids
extracted from 0.1 g leaf tissue infected by GFLV), lane 6: negative control
(E. coli with pET26 empty vector used for expression steps), lane M: DNA
molecular weight marker (1 kb).
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